Welcome to our dedicated page for Agilent Technologies news (Ticker: A), a resource for investors and traders seeking the latest updates and insights on Agilent Technologies stock.
Agilent Technologies Inc., originally spun out of Hewlett-Packard in 1999, has evolved into a leading firm in the life sciences and diagnostics sector. The company specializes in creating advanced measurement technologies that serve a vast range of customers across various industries.
The company's core business revolves around three main segments: life science and applied tools, cross lab (which includes consumables and services related to life sciences and applied tools), and diagnostics and genomics. These segments collectively cater to a broad spectrum of markets, including biopharmaceuticals, chemicals, advanced materials, clinical labs, environmental testing, forensics, food safety, academic research, and government-related organizations.
Agilent's geographical reach is extensive, with significant operations in the U.S. and China. The company is committed to addressing global trends impacting human health and the environment and continuously anticipates future scientific needs.
Agilent provides comprehensive laboratory solutions that enhance the efficiency of laboratories, from sample preparation to data interpretation and management. Their instruments, software, services, and consumables are designed to meet the most complex laboratory demands, empowering scientists and researchers worldwide to make impactful discoveries and improvements in various fields.
Recent achievements include advancements in biopharmaceutical technology, collaborations with leading research institutions, and the launch of state-of-the-art diagnostic tools. The company also emphasizes sustainable practices and innovations aimed at improving human health and environmental outcomes.
Agilent Technologies Inc. (NYSE: A) has unveiled its new Agilent 7850 ICP-MS System, designed to enhance productivity in ICP-MS analysis workflows. This innovative instrument features smart tools aimed at minimizing common time traps that can waste time and increase costs, particularly benefiting less experienced users in small to medium contract labs. The 7850's advanced software streamlines instrument setup and workflow, helping labs achieve high-quality results efficiently. With a revenue of $5.34 billion in fiscal 2020, Agilent continues to lead in the life sciences and diagnostics sector.
Agilent Technologies Inc. (NYSE: A) has launched the Biomarker Pathologist Training Program, aimed at enhancing the ability of pathologists to accurately score biomarkers. This global initiative, initially available in Europe and North America, leverages Agilent's expertise in companion diagnostics and partnerships with pharmaceutical firms. The program includes both basic and advanced training, offered digitally via Pathcore Scholar. It is designed to improve patient outcomes by ensuring high concordance in biomarker scoring, critical for the increasing prevalence of targeted therapies in oncology.
Agilent Technologies reported Q4 revenue of $1.48 billion, an 8% increase year-over-year, with GAAP net income of $222 million (71 cents per share). Non-GAAP net income reached $305 million (98 cents per share), surpassing last year's figures. The Life Sciences and Applied Markets Group posted $671 million in revenue, while the Diagnostics and Genomics Group generated $294 million. For fiscal year 2021, revenue is projected between $5.6 billion and $5.7 billion, with non-GAAP EPS guidance of $3.57 to $3.67.
Agilent Technologies Inc. (NYSE: A) launched the NanoDis System for nanoparticle dissolution testing, designed to ensure compliance with 21 CFR Part 11 regulations. Developed in collaboration with MyBiotech GmbH, this system enhances the efficiency of R&D and manufacturing workflows by providing an automated process for consistent QC of new drug formulations. The NanoDis System is recognized as a finalist for the CPhI Pharma Awards, highlighting its innovative role in advancing pharmaceutical quality control.
Agilent Technologies, Inc. (NYSE: A) has announced an increase in its quarterly dividend to 19.4 cents per share, reflecting an 8% rise over the previous quarter. The dividend payment is set for January 27, 2021, to shareholders on record as of January 5, 2021. Future dividend amounts are subject to board approval. Agilent continues to operate as a leader in life sciences, diagnostics, and applied chemical markets, generating $5.16 billion in revenue in fiscal 2019 and employing over 16,300 individuals globally.
Agilent Technologies (NYSE: A) has awarded the Agilent Thought Leader Award to professors Carl H. June and Michael Milone for their contributions to CAR T-cell cancer immunotherapy, notably the co-development of tisagenlecleucel (Kymriah™). The partnership aims to establish standards in cell-based cancer therapeutics through advanced CRISPR technology and Agilent's instruments such as the xCELLigence RTCA eSight and 6546 LC/Q-TOF Mass Spectrometer. This collaboration is expected to enhance cancer treatment methodologies and improve the quality of T-cell engineering.
Agilent Technologies (NYSE: A) has received FDA approval for the use of PD-L1 IHC 22C3 pharmDx to help identify patients with triple-negative breast cancer (TNBC) for treatment with KEYTRUDA® (pembrolizumab). This assay is the only FDA-approved companion diagnostic for this purpose, enhancing the ability of pathologists to determine PD-L1 expression, a key biomarker for the therapy. With this approval, Agilent strengthens its role in drug/diagnostic co-development, marking the seventh cancer type for which the test has been approved.
Agilent Technologies Inc. (NYSE: A) has partnered with SGS to develop the SGS AXYS Method 16130, a new gas chromatography/tandem mass spectrometry method approved by the US EPA for analyzing dioxins. This method addresses the limitations of the older EPA 1613B method, which relied on outdated technology. The new method enhances testing accuracy and lowers operational costs, empowering more laboratories to conduct essential environmental testing. This collaboration marks a significant step in Agilent's commitment to environmental health and safety.
Agilent Technologies (NYSE: A) will announce its fourth-quarter fiscal year 2020 financial results on November 23, after market close. A live webcast of the investor conference call will follow. Additionally, the company has scheduled a virtual Analyst and Investor meeting on December 9, where senior management will discuss strategies for enhancing revenue growth and shareholder value, including a live Q&A session. Agilent generated $5.16 billion in revenue in fiscal 2019, employing 16,300 people globally.
FAQ
What is the current stock price of Agilent Technologies (A)?
What is the market cap of Agilent Technologies (A)?
What does Agilent Technologies Inc. specialize in?
When was Agilent Technologies Inc. founded?
What are the main business segments of Agilent Technologies Inc.?
Which industries does Agilent Technologies Inc. serve?
Where are Agilent Technologies Inc.'s main operations located?
What recent achievements has Agilent Technologies Inc. made?
How does Agilent Technologies Inc. contribute to laboratory efficiency?
What sustainable practices does Agilent Technologies Inc. emphasize?
Why do scientists and researchers trust Agilent Technologies Inc.?
What kind of global issues does Agilent Technologies Inc. address?
